Crescent Biopharma (CBIO) Receivables - Other (2013 - 2025)
Crescent Biopharma (CBIO) posted quarterly Receivables - Other of $78762.0 for Q1 2025, down 28.36% year-over-year from $109946.0 in Q1 2024, and down 42.33% quarter-over-quarter from $136580.0 in Q4 2024.
Crescent Biopharma (CBIO) Receivables - Other (2013 - 2025) Analysis & Trends
Crescent Biopharma (CBIO) has reported Receivables - Other for 13 consecutive years, with $78762.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Receivables - Other fell 28.36% year-over-year to $78762.0; the TTM figure through Mar 2025 stood at $78762.0 (down 28.36% YoY), while the FY2024 annual figure was $136580.0, down 22.32% from the prior year.
- Receivables - Other declined to $78762.0 in Q1 2025 per CBIO's latest filing, from $136580.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $444568.0 in Q1 2021 and bottomed at $1347.0 in Q4 2021.
- Historically, Receivables - Other has averaged $122088.6 across 5 years, with a median of $109946.0 in 2024.
- On a YoY basis, Receivables - Other climbed as much as 10591.61% in 2022 and fell as far as 98.93% in 2022.
- Crescent Biopharma's Receivables - Other stood at $1347.0 in 2021, then surged by 10591.61% to $144016.0 in 2022, then climbed by 22.08% to $175820.0 in 2023, then fell by 22.32% to $136580.0 in 2024, then tumbled by 42.33% to $78762.0 in 2025.
- Business Quant data shows CBIO's Receivables - Other at $78762.0 in Q1 2025, $136580.0 in Q4 2024, and $50255.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - |
| 10 | Crescent Biopharma | 1.06 Bn | 886.89 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 78,762.00 |
| Mar 31, 2025 | 78,762.00 |
| Dec 31, 2024 | 136,580.00 |
| Dec 31, 2024 | 136,580.00 |
| Sep 30, 2024 | 50,255.00 |
| Sep 30, 2024 | 50,255.00 |
| Jun 30, 2024 | 76,710.00 |
| Jun 30, 2024 | 76,710.00 |
| Mar 31, 2024 | 109,946.00 |
| Mar 31, 2024 | 109,946.00 |
| Dec 31, 2023 | 175,820.00 |
| Dec 31, 2023 | 175,820.00 |
| Sep 30, 2023 | 188,949.00 |
| Sep 30, 2023 | 188,949.00 |
| Jun 30, 2023 | 215,368.00 |
| Jun 30, 2023 | 215,368.00 |
| Mar 31, 2023 | 234,114.00 |
| Mar 31, 2023 | 234,114.00 |
| Dec 31, 2022 | 144,016.00 |
| Dec 31, 2022 | 144,016.00 |